Bellevue Group AG Sells 37,658 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Bellevue Group AG lessened its position in Omnicell, Inc. (NASDAQ:OMCL) by 16.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 197,714 shares of the company’s stock after selling 37,658 shares during the quarter. Bellevue Group AG owned 0.43% of Omnicell worth $8,620,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in OMCL. Victory Capital Management Inc. lifted its stake in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after purchasing an additional 1,138,921 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Omnicell during the 3rd quarter worth approximately $32,721,000. Pacer Advisors Inc. boosted its holdings in Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after acquiring an additional 508,789 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Omnicell by 750.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after acquiring an additional 259,463 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on OMCL shares. Benchmark reissued a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Wells Fargo & Company raised their price objective on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $52.00.

Omnicell Price Performance

Shares of OMCL stock opened at $46.59 on Friday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The company’s 50 day moving average is $44.55 and its 200 day moving average is $37.99.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.